|
|
Technologiepark 4
Ghent/Zwijnaarde, 09052 Belgium
phone:+32 9 262.00.00
fax:+32 9 262.00.01
|
|
| Symbol |
ABLX |
| Exchange |
BB |
| Founded |
2001 |
| Employees |
200 |
|
|
| www.ablynx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Nanobodies to treat a range of diseases including arthritis and inflammatory bowel disease. |
|
| Management |
| Edwin Moses, Chief Executive Officer and Chairman of the Board; Wim Ottevaere, Chief Financial Officer; Eva-Lotta Allan, Chief Business Officer; Josefin-Beate (Josi) Holz, Chief Medical Officer; Debbie Law, Chief Scientific Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| immunogenicity, anti-thrombotic, percutaneous, vivo efficacy, intravenously |
|
|
|
| Description |
|
Ablynx is engaged in the discovery and development of Nanobodies to treat a range of serious human diseases. Nanobodies are a novel class of antibody-derived therapeutic proteins. Because of their small size, unique structure and extreme stability, Nanobodies combine the advantages of conventional antibody therapeutics with the key features of small-molecule drugs. |
|
| Products / Services |
Ablynx's discovery platform has resulted in three Nanobody development candidates. Ablynx's lead programme, a novel anti-thrombotic, ALX-0081, became the first ever single domain antibody to enter clinical trials and Ablynx reported the final positive results from its Phase I study in December 2007. Following these positive results, Ablynx initiated a Phase Ib multiple-dose study in May 2008, directly in the target patient population rather than healthy volunteers for ALX-0081. In December 2008, Ablynx reported positive results confirming that ALX-0081 had reached the primary endpoint of the Phase Ib study, demonstrating the desired pharmacological effect. In December 2008 Ablynx initiated its second clinical development programme, ALX-0681. ALX-0681, also an anti-thrombotic, which is administered subcutaneously, entered a healthy volunteer Phase I study. Ablynx's preclinical candidate ALX-0141 is a fully humanized Nanobody that targets the Receptor Activator for Nuclear Factor kappa B Ligand (RANKL), a molecule important in bone metabolism. Ablynx aims to develop ALX-0141 for a range of indications including the treatment of osteoporosis.
Ablynx's partner Wyeth Pharmaceuticals also initiated a healthy volunteer Phase I study in December 2008 for its anti-TNF alpha Nanobody. There are three Nanobodies in clinical development.
|
|
| Technology / Differentiation |
| Nanobodies are antibody-derived therapeutic proteins that contain the unique structural and functional properties of naturally-occurring heavy-chain antibodies. The Nanobody technology was originally developed following the discovery that camelidae (camels and llamas) possess fully functional antibodies that lack light chains. These heavy-chain antibodies contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Importantly, the cloned and isolated VHH domain is a perfectly stable polypeptide harbouring the full antigen-binding capacity of the original heavy-chain antibody. These newly discovered VHH domains with their unique structural and functional properties form the basis of a new generation of therapeutic antibodies which Ablynx has named Nanobodies. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
